Table 2.

Between group changes in sleep continuity variables compared to placebo.

	Estimate	SE	Lower 95% CI	Upper 95% CI	p-value	Effect Size
Sleep latency
CBT-I + Placebo vs. Placebo	-18.62	5.25	-29.14	-8.10	<0.001**	-0.67
CBT-I + Armodafinil vs. Placebo	-16.16	5.27	-26.73	-5.59	0.003**	-0.58
Armodafinil vs. Placebo	7.98	5.68	-3.45	19.41	0.17	0.29
CBT-I + Armodafinil vs. CBT-I + Placebo	2.46	4.67	-6.70	11.61	0.60	0.09
Wake after sleep onset
CBT-I + Placebo vs. Placebo	-10.00	5.50	-20.96	0.96	0.07	-0.48
CBT-I + Armodafinil vs. Placebo	-13.14	5.59	-24.27	-2.01	0.02	-0.64
Armodafinil vs. Placebo	10.23	7.56	-5.05	25.51	0.18	0.50
CBT-I + Armodafinil vs. CBT-I + Placebo	-3.14	5.16	-13.24	6.97	0.54	-0.15
Total sleep time
CBT-I + Placebo vs. Placebo	-28.69	19.43	-67.65	10.27	0.15	-0.39
CBT-I + Armodafinil vs. Placebo	-16.00	20.36	-56.93	24.93	0.44	-0.22
Armodafinil vs. Placebo	-51.30	21.80	-95.24	-7.37	0.02	-0.69
CBT-I + Armodafinil vs. CBT-I + Placebo	12.69	17.68	-21.97	47.35	0.47	0.17

^*P < 0.01,

^**P < 0.001 A significance level of 0.0125 was used to adjust for multiple comparisons. (Asterisks denote improvements compared to placebo for between group analyses.); All analyses used multiple imputation; P-values for between group analyses are from ANCOVA controlling for values at time of consent; Effect size is Cohen’s D.